Sunday November 8 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Ventana Clinical Research Corporation

Ventana was founded in 1997 by Dr. Edward Sellers, Dr. Myroslava Romach, Dr. Neil Shear and Gail Somer after having established international reputations with more than thirty years of quality, innovative research and consulting at the University of Toronto, University Health Network, the Addiction Research Foundation and Sunnybrook and Women's College Health Sciences Centre in Toronto. Starting as a small independent research group with inpatient beds for early-phase clinical drug trials within the hospital setting, the company soon expanded in 2001 to a stand-alone facility with a 16-bed capacity and approximately 50 staff members.

The company has consistently shown growth in both revenue and resources and was recently listed as one of Canada's Fastest-Growing Companies by Profit Magazine.

Due to the tremendous success of the company, the company again expanded in 2004 to a custom-designed, dedicated clinical research facility with an inpatient capacity of 64 beds.


Contact Details:
720 King Street West, 7th Floor
Toronto
Ontario
M5V 2T3
Canada
Tel:(416) 963-4922
Fax:(416) 963-9732
Email:info@ventana-crc.com
WWW:

www.ventana-crc.com/




Loading...

Recent Publications by Ventana Clinical Research Corporation:

In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission.
Neurotropic effects of endo- and exo-cannabinoids are largely caused by...
14th April, 2007
Ventana Clinical Research Corporation, Toronto, ON, Canada. Curr Opin Pharmacol. 2007 Feb;7(1):62-8. Epub 2006 Dec 15.
DOI Direct Link
Relative abuse potential of opioid formulations in Canada: a structured field study.
INTRODUCTION: While prescription opioids can improve quality of life...
16th March, 2007
Ventana Clinical Research Corporation, Toronto, Ontario, Canada. J Opioid Manag. 2006 Jul-Aug;2(4):219-27.
Efalizumab, a reversible T-cell modulator for psoriasis.
The humanized monoclonal antibody (MAb) efalizumab (Raptiva) was developed...
13th September, 2006
Sunnybrook & Women's College Health Sciences Centre, University of Toronto J Cutan Med Surg. 2006;9 Suppl 1:4-9.
DOI Direct Link
Research design strategies to evaluate the impact of formulations on abuse liability.
Scheduling of a chemical drug substance under the Controlled Substances...
26th July, 2006
Ventana Clinical Research Corporation, Toronto, Canada. Drug Alcohol Depend. 2006 Jun;83 Suppl 1:S52-62. Epub 2006 Mar 22.
DOI Direct Link

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 3313 times since April 2007, the link to the organisation's website has been followed 860 times

Recent Search Terms used to find this page: Toronto drug research studies | ventenna drug studies | toronto medical research companies | drug research studies toronto | Gail Somer | drug studies toronto | drug research studies toronto | gail somer | clinical research in toronto | drug study toronto | .

Search for more companies in Toronto

Search for more companies in Ontario



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Ventana Clinical Research Corporation

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.